论文信息 - Consistency of continual reassessment method under model misspecification

Consistency of continual reassessment method under model misspecification

SUMMARY This paper studies large sample behaviour of the continual reassessment method used to determine the target dose levels in phase I clinical trials. A sequential maximum likelihood procedure is investigated for local estimation of a given targeted toxicity level. Consistency and asymptotic normality for the maximum likelihood estimates are established under model misspecification and it is shown that, in general, the recommended dose level will converge to the target level. There are, however, situations in which the recommended dose may converge to a level close to the target level, but not necessarily the closest. This contrasts with the conclusions of O'Quigley, Pepe & Fisher (1990) and we describe this situation as well as providing the conditions under which convergence is assured.

John O'Quigley | J. O'Quigley | L. Z. Shen | Larry Z. Shen

[1] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[2] M. Silvapulle. On the Existence of Maximum Likelihood Estimators for the Binomial Response Models , 1981 .

[3] Changbao Wu. Maximum likelihood recursion and stochastic approximation in sequential designs , 1986 .

[4] C. F. Wu,et al. Efficient Sequential Designs with Binary Data , 1985 .

[5] P. J. Huber. The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .

[6] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.

[7] J O'Quigley,et al. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. , 1992, Biometrics.

[8] S. Chevret,et al. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. , 1991, Statistics in medicine.